Is Shopify Stock a Good Buy Now?
eCommerce technology platform Shopify (NASDAQ:SHOP) delivered impressive returns in 2025…
Sell
31
ADIL Quote, Financials, Valuation and Earnings
Last price:
$0.24
Seasonality move
:
27.39%
Day range:
$0.23 - $0.25
52-week range:
$0.22 - $1.30
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
--
P/B ratio:
1.29x
Volume:
258.3K
Avg. volume:
331K
1-year change:
-76.27%
Market cap:
$5.8M
Revenue:
--
EPS (TTM):
-$0.93
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
ADIL
Adial Pharmaceuticals, Inc.
|
-- | -$0.10 | -- | -73.94% | $2.17 |
|
ACXP
Acurx Pharmaceuticals, Inc.
|
-- | -$0.94 | -- | -69.54% | $61.70 |
|
NBY
NovaBay Pharmaceuticals, Inc.
|
$3M | -$0.88 | 14.03% | -95.43% | $0.85 |
|
OGEN
Oragenics, Inc.
|
-- | -- | -- | -- | $2.00 |
|
PTN
Palatin Technologies
|
-- | -$0.17 | -- | -67.93% | -- |
|
TOVX
Theriva Biologics, Inc.
|
-- | -$0.37 | -- | -94.42% | $7.00 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
ADIL
Adial Pharmaceuticals, Inc.
|
$0.24 | $2.17 | $5.8M | -- | $0.00 | 0% | -- |
|
ACXP
Acurx Pharmaceuticals, Inc.
|
$2.93 | $61.70 | $4.5M | -- | $0.00 | 0% | -- |
|
NBY
NovaBay Pharmaceuticals, Inc.
|
$19.16 | $0.85 | $2.4B | 32.19x | $0.80 | 0% | 37.23x |
|
OGEN
Oragenics, Inc.
|
$0.83 | $2.00 | $683.9K | -- | $0.00 | 0% | 0.53x |
|
PTN
Palatin Technologies
|
$0.09 | -- | $2.4M | -- | $0.00 | 0% | -- |
|
TOVX
Theriva Biologics, Inc.
|
$0.21 | $7.00 | $7.2M | -- | $0.00 | 0% | 0.33x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
ADIL
Adial Pharmaceuticals, Inc.
|
-- | -0.319 | -- | 3.99x |
|
ACXP
Acurx Pharmaceuticals, Inc.
|
-- | 3.493 | -- | 2.39x |
|
NBY
NovaBay Pharmaceuticals, Inc.
|
37.25% | -3.190 | 8.08% | 1.85x |
|
OGEN
Oragenics, Inc.
|
3.86% | 0.905 | 36.62% | 3.97x |
|
PTN
Palatin Technologies
|
-- | 1.358 | -- | -- |
|
TOVX
Theriva Biologics, Inc.
|
29.07% | -2.522 | 66.16% | 0.68x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
ADIL
Adial Pharmaceuticals, Inc.
|
-$100 | -$1.8M | -181.56% | -181.56% | -- | -$1.8M |
|
ACXP
Acurx Pharmaceuticals, Inc.
|
-- | -$2M | -358.38% | -358.38% | -- | -$1.9M |
|
NBY
NovaBay Pharmaceuticals, Inc.
|
$42K | -$1.2M | -208.55% | -306.03% | -224.38% | -$1.8M |
|
OGEN
Oragenics, Inc.
|
-- | -$3.1M | -311.49% | -509.23% | -- | -$3M |
|
PTN
Palatin Technologies
|
-- | -- | -- | -- | -- | -- |
|
TOVX
Theriva Biologics, Inc.
|
-$28K | -$4.4M | -148.18% | -171.04% | -- | -$4.3M |
Adial Pharmaceuticals, Inc. vs. Competitors
-
Which has Higher Returns ADIL or ACXP?
Acurx Pharmaceuticals, Inc. has a net margin of -- compared to Adial Pharmaceuticals, Inc.'s net margin of --. Adial Pharmaceuticals, Inc.'s return on equity of -181.56% beat Acurx Pharmaceuticals, Inc.'s return on equity of -358.38%.
Company Gross Margin Earnings Per Share Invested Capital ADILAdial Pharmaceuticals, Inc.-- -$0.08 $4.5M ACXPAcurx Pharmaceuticals, Inc.-- -$1.23 $3.6M -
What do Analysts Say About ADIL or ACXP?
Adial Pharmaceuticals, Inc. has a consensus price target of $2.17, signalling upside risk potential of 795.32%. On the other hand Acurx Pharmaceuticals, Inc. has an analysts' consensus of $61.70 which suggests that it could grow by 2005.8%. Given that Acurx Pharmaceuticals, Inc. has higher upside potential than Adial Pharmaceuticals, Inc., analysts believe Acurx Pharmaceuticals, Inc. is more attractive than Adial Pharmaceuticals, Inc..
Company Buy Ratings Hold Ratings Sell Ratings ADILAdial Pharmaceuticals, Inc.2 0 0 ACXPAcurx Pharmaceuticals, Inc.1 0 0 -
Is ADIL or ACXP More Risky?
Adial Pharmaceuticals, Inc. has a beta of 1.193, which suggesting that the stock is 19.261% more volatile than S&P 500. In comparison Acurx Pharmaceuticals, Inc. has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.
-
Which is a Better Dividend Stock ADIL or ACXP?
Adial Pharmaceuticals, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Acurx Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Adial Pharmaceuticals, Inc. pays -- of its earnings as a dividend. Acurx Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios ADIL or ACXP?
Adial Pharmaceuticals, Inc. quarterly revenues are --, which are smaller than Acurx Pharmaceuticals, Inc. quarterly revenues of --. Adial Pharmaceuticals, Inc.'s net income of -$1.8M is higher than Acurx Pharmaceuticals, Inc.'s net income of -$2M. Notably, Adial Pharmaceuticals, Inc.'s price-to-earnings ratio is -- while Acurx Pharmaceuticals, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Adial Pharmaceuticals, Inc. is -- versus -- for Acurx Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income ADILAdial Pharmaceuticals, Inc.-- -- -- -$1.8M ACXPAcurx Pharmaceuticals, Inc.-- -- -- -$2M
-
Which has Higher Returns ADIL or NBY?
NovaBay Pharmaceuticals, Inc. has a net margin of -- compared to Adial Pharmaceuticals, Inc.'s net margin of -255.85%. Adial Pharmaceuticals, Inc.'s return on equity of -181.56% beat NovaBay Pharmaceuticals, Inc.'s return on equity of -306.03%.
Company Gross Margin Earnings Per Share Invested Capital ADILAdial Pharmaceuticals, Inc.-- -$0.08 $4.5M NBYNovaBay Pharmaceuticals, Inc.8.06% -$0.22 $2.6M -
What do Analysts Say About ADIL or NBY?
Adial Pharmaceuticals, Inc. has a consensus price target of $2.17, signalling upside risk potential of 795.32%. On the other hand NovaBay Pharmaceuticals, Inc. has an analysts' consensus of $0.85 which suggests that it could fall by -95.56%. Given that Adial Pharmaceuticals, Inc. has higher upside potential than NovaBay Pharmaceuticals, Inc., analysts believe Adial Pharmaceuticals, Inc. is more attractive than NovaBay Pharmaceuticals, Inc..
Company Buy Ratings Hold Ratings Sell Ratings ADILAdial Pharmaceuticals, Inc.2 0 0 NBYNovaBay Pharmaceuticals, Inc.1 0 0 -
Is ADIL or NBY More Risky?
Adial Pharmaceuticals, Inc. has a beta of 1.193, which suggesting that the stock is 19.261% more volatile than S&P 500. In comparison NovaBay Pharmaceuticals, Inc. has a beta of 0.093, suggesting its less volatile than the S&P 500 by 90.725%.
-
Which is a Better Dividend Stock ADIL or NBY?
Adial Pharmaceuticals, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. NovaBay Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.80 per share. Adial Pharmaceuticals, Inc. pays -- of its earnings as a dividend. NovaBay Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios ADIL or NBY?
Adial Pharmaceuticals, Inc. quarterly revenues are --, which are smaller than NovaBay Pharmaceuticals, Inc. quarterly revenues of $521K. Adial Pharmaceuticals, Inc.'s net income of -$1.8M is lower than NovaBay Pharmaceuticals, Inc.'s net income of -$1.3M. Notably, Adial Pharmaceuticals, Inc.'s price-to-earnings ratio is -- while NovaBay Pharmaceuticals, Inc.'s PE ratio is 32.19x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Adial Pharmaceuticals, Inc. is -- versus 37.23x for NovaBay Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income ADILAdial Pharmaceuticals, Inc.-- -- -- -$1.8M NBYNovaBay Pharmaceuticals, Inc.37.23x 32.19x $521K -$1.3M
-
Which has Higher Returns ADIL or OGEN?
Oragenics, Inc. has a net margin of -- compared to Adial Pharmaceuticals, Inc.'s net margin of --. Adial Pharmaceuticals, Inc.'s return on equity of -181.56% beat Oragenics, Inc.'s return on equity of -509.23%.
Company Gross Margin Earnings Per Share Invested Capital ADILAdial Pharmaceuticals, Inc.-- -$0.08 $4.5M OGENOragenics, Inc.-- -$1.96 $10.2M -
What do Analysts Say About ADIL or OGEN?
Adial Pharmaceuticals, Inc. has a consensus price target of $2.17, signalling upside risk potential of 795.32%. On the other hand Oragenics, Inc. has an analysts' consensus of $2.00 which suggests that it could grow by 140.65%. Given that Adial Pharmaceuticals, Inc. has higher upside potential than Oragenics, Inc., analysts believe Adial Pharmaceuticals, Inc. is more attractive than Oragenics, Inc..
Company Buy Ratings Hold Ratings Sell Ratings ADILAdial Pharmaceuticals, Inc.2 0 0 OGENOragenics, Inc.1 0 0 -
Is ADIL or OGEN More Risky?
Adial Pharmaceuticals, Inc. has a beta of 1.193, which suggesting that the stock is 19.261% more volatile than S&P 500. In comparison Oragenics, Inc. has a beta of 0.903, suggesting its less volatile than the S&P 500 by 9.685%.
-
Which is a Better Dividend Stock ADIL or OGEN?
Adial Pharmaceuticals, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Oragenics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Adial Pharmaceuticals, Inc. pays -- of its earnings as a dividend. Oragenics, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios ADIL or OGEN?
Adial Pharmaceuticals, Inc. quarterly revenues are --, which are smaller than Oragenics, Inc. quarterly revenues of --. Adial Pharmaceuticals, Inc.'s net income of -$1.8M is higher than Oragenics, Inc.'s net income of -$3.1M. Notably, Adial Pharmaceuticals, Inc.'s price-to-earnings ratio is -- while Oragenics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Adial Pharmaceuticals, Inc. is -- versus 0.53x for Oragenics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income ADILAdial Pharmaceuticals, Inc.-- -- -- -$1.8M OGENOragenics, Inc.0.53x -- -- -$3.1M
-
Which has Higher Returns ADIL or PTN?
Palatin Technologies has a net margin of -- compared to Adial Pharmaceuticals, Inc.'s net margin of --. Adial Pharmaceuticals, Inc.'s return on equity of -181.56% beat Palatin Technologies's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital ADILAdial Pharmaceuticals, Inc.-- -$0.08 $4.5M PTNPalatin Technologies-- -- -- -
What do Analysts Say About ADIL or PTN?
Adial Pharmaceuticals, Inc. has a consensus price target of $2.17, signalling upside risk potential of 795.32%. On the other hand Palatin Technologies has an analysts' consensus of -- which suggests that it could grow by 7338.9%. Given that Palatin Technologies has higher upside potential than Adial Pharmaceuticals, Inc., analysts believe Palatin Technologies is more attractive than Adial Pharmaceuticals, Inc..
Company Buy Ratings Hold Ratings Sell Ratings ADILAdial Pharmaceuticals, Inc.2 0 0 PTNPalatin Technologies0 0 0 -
Is ADIL or PTN More Risky?
Adial Pharmaceuticals, Inc. has a beta of 1.193, which suggesting that the stock is 19.261% more volatile than S&P 500. In comparison Palatin Technologies has a beta of 0.939, suggesting its less volatile than the S&P 500 by 6.103%.
-
Which is a Better Dividend Stock ADIL or PTN?
Adial Pharmaceuticals, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Palatin Technologies offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Adial Pharmaceuticals, Inc. pays -- of its earnings as a dividend. Palatin Technologies pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios ADIL or PTN?
Adial Pharmaceuticals, Inc. quarterly revenues are --, which are larger than Palatin Technologies quarterly revenues of --. Adial Pharmaceuticals, Inc.'s net income of -$1.8M is higher than Palatin Technologies's net income of --. Notably, Adial Pharmaceuticals, Inc.'s price-to-earnings ratio is -- while Palatin Technologies's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Adial Pharmaceuticals, Inc. is -- versus -- for Palatin Technologies. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income ADILAdial Pharmaceuticals, Inc.-- -- -- -$1.8M PTNPalatin Technologies-- -- -- --
-
Which has Higher Returns ADIL or TOVX?
Theriva Biologics, Inc. has a net margin of -- compared to Adial Pharmaceuticals, Inc.'s net margin of --. Adial Pharmaceuticals, Inc.'s return on equity of -181.56% beat Theriva Biologics, Inc.'s return on equity of -171.04%.
Company Gross Margin Earnings Per Share Invested Capital ADILAdial Pharmaceuticals, Inc.-- -$0.08 $4.5M TOVXTheriva Biologics, Inc.-- -$0.45 $9.5M -
What do Analysts Say About ADIL or TOVX?
Adial Pharmaceuticals, Inc. has a consensus price target of $2.17, signalling upside risk potential of 795.32%. On the other hand Theriva Biologics, Inc. has an analysts' consensus of $7.00 which suggests that it could grow by 3158.85%. Given that Theriva Biologics, Inc. has higher upside potential than Adial Pharmaceuticals, Inc., analysts believe Theriva Biologics, Inc. is more attractive than Adial Pharmaceuticals, Inc..
Company Buy Ratings Hold Ratings Sell Ratings ADILAdial Pharmaceuticals, Inc.2 0 0 TOVXTheriva Biologics, Inc.1 1 0 -
Is ADIL or TOVX More Risky?
Adial Pharmaceuticals, Inc. has a beta of 1.193, which suggesting that the stock is 19.261% more volatile than S&P 500. In comparison Theriva Biologics, Inc. has a beta of 0.343, suggesting its less volatile than the S&P 500 by 65.729%.
-
Which is a Better Dividend Stock ADIL or TOVX?
Adial Pharmaceuticals, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Theriva Biologics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Adial Pharmaceuticals, Inc. pays -- of its earnings as a dividend. Theriva Biologics, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios ADIL or TOVX?
Adial Pharmaceuticals, Inc. quarterly revenues are --, which are smaller than Theriva Biologics, Inc. quarterly revenues of --. Adial Pharmaceuticals, Inc.'s net income of -$1.8M is higher than Theriva Biologics, Inc.'s net income of -$4.4M. Notably, Adial Pharmaceuticals, Inc.'s price-to-earnings ratio is -- while Theriva Biologics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Adial Pharmaceuticals, Inc. is -- versus 0.33x for Theriva Biologics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income ADILAdial Pharmaceuticals, Inc.-- -- -- -$1.8M TOVXTheriva Biologics, Inc.0.33x -- -- -$4.4M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Will The Magnificent 7 Stocks Go Up This Year?
2025 was another banner year for the Magnificent Seven stocks,…
Why Did Planet Labs Stock Rally So Much?
Satellite imaging startup Planet Labs (NYSE:PL), after years of disappointing…
Stock Ideas
Buy
52
Is NVDA Stock a Buy?
Market Cap: $4.5T
P/E Ratio: 63x
Buy
65
Is GOOG Stock a Buy?
Market Cap: $4T
P/E Ratio: 41x
Buy
51
Is GOOGL Stock a Buy?
Market Cap: $4T
P/E Ratio: 41x
Alerts
Buy
100
ATGL alert for Jan 10
Alpha Technology Group Ltd. [ATGL] is up 47.05% over the past day.
Buy
71
NAIL alert for Jan 10
Direxion Daily Homebuilders & Supplies Bull 3X Shs [NAIL] is up 18.52% over the past day.
Buy
54
LGIH alert for Jan 10
LGI Homes, Inc. [LGIH] is up 13.81% over the past day.
